Finance ForgeBETA
Crear cuenta gratis
1)Empresas2)Rankings3)Iniciar sesión
Finance Forge Terminal v1.49.5
PrivacidadTérminosCookiesAviso Legal
● Connected
MREO US Equity
Mereo BioPharma Group plc
0.31USD▼ 9.97%
Healthcare
Biotechnology
96)Comparar97)Tesis →
Market Cap
$50M
Shares Outstanding
160M
Net Income (TTM)
−$28M
FCF (TTM)
−$25M
— Annual —FY2025
Revenue
$500,000
Operating Margin
-8021.4%
Net Margin
-8375.6%
FCF Margin
-6198.2%
ROE
-102.3%
ROCE
-96.4%
Current Ratio
10.46
FCF / Share
-0.19
Book Value / Share
0.26
MREO US Equity
0.31USD▼ 9.97%
Tesis →

Mereo BioPharma Group plc (MREO): análisis fundamental y valoración

Mereo BioPharma Group plc cotiza a 0.31 USD y tiene una capitalización bursátil de $50M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud

Price History
Loading...
Perfil
BolsaNasdaqPaísUnited KingdomEmpleados39Beta0.14Web↗ www.mereobiopharma.com

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase …

Múltiplos de Valoración
P/E (Annual)
—
P/E (TTM)
—
P/FCF (Annual)
—
P/FCF (TTM)
—
EV/EBITDA
—
EV/Revenue
—
P/Sales
100.6×
P/Book
1.2×
Rentabilidad (Último Anual)
Gross Margin
—
Operating Margin
-8021.4%
Net Margin
-8375.6%
FCF Margin
-6198.2%
ROE
-102.3%
ROCE
-96.4%
ROA
-91.2%
Effective Tax Rate
0.0%
Métricas TTM
Revenue TTM
—
Gross Profit TTM
—
Operating Income TTM
−$34M
Net Income TTM
−$28M
FCF TTM
−$25M
EPS TTM
-0.03
Quarters Used
4
TTM Period
2025-09-30 → 2026-06-30
Solidez del Balance
Net Debt
—
Net Debt / EBITDA
—
Debt / Equity
—
Current Ratio
10.46
Interest Coverage
-157.3×
Working Capital
$41M
Book Value / Share
0.26
Net Debt / Share
—
Crecimiento (YoY)
Revenue YoY
—
Net Income YoY
+3.2%
FCF YoY
+5.6%
EPS Diluted YoY
+16.7%
Retorno al Accionista
Dividend Yield
—
Payout Ratio
—
FCF / Share
-0.19
CapEx % Revenue
4.0%
Rev / Employee
12,820
Empresas similares
Smart Money
vs Sector: Healthcare (1130 empresas)
MétricaMREOMediana SectorΔ
Gross Margin—57.0%—
Operating Margin-8021.4%-38.6%-7982.8%
Net Margin-8375.6%-33.6%-8342.0%
FCF Margin-6198.2%-13.9%-6184.3%
ROE-102.3%-40.4%-61.9%
ROA-91.2%-32.0%-59.2%
Current Ratio10.462.84+7.62
Debt / Equity—0.28—
Scoring Fundamental
Capital Allocation
1/ 8Débil
✗FCF+Free cash flow positivo
✗FCFmMargen FCF > 10%
✗DilucSin dilución significativa (< 2%/año en 3 años)
✗Rev↑Revenue CAGR 3 años > 5%
✗ROCERetorno sobre capital empleado > 10%
✗DeudaDeuda neta/EBITDA < 3× (o posición de caja neta)
✗Mg↑Margen operativo ≥ hace 2-3 años (tolerancia -2pp)
✓Inv.R&D + Capex > 3% de revenue (reinversión en el negocio)